Biogen adds more immune drugs in $1B buyout of secretive startup Raythera

Biogen adds more immune drugs in $1B buyout of secretive startup Raythera is a pharma and life sciences industry update from BioPharma Dive. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Kristin Jensen · 2026-06-18

The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents Raythera secured provide important clues.

Source: BioPharma Dive